'We see this warranty as a good way to give customers a financial backstop on the cybersecurity investments they make with Fulcrum IT Partners,’ says Fulcrum IT Partners US and Canada President Kyle ...
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve ...
The company will complete a full evaluation of the data it received this week and plans to share the results at an upcoming medical meeting. In light of these results, the company plans to suspend the ...
Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027. The ...
Tuesday, the FDA lifted the clinical hold on Fulcrum Therapeutics Inc's FULC Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease (SCD). Following ...
Zacks Investment Research on MSN
FULC stock crashes as cancer risk forces its only drug program's end
Fulcrum Therapeutics FULC saw its stock crash 51.1% on Tuesday after announcing the discontinuation of its lead candidate, pociredir, for sickle cell disease (SCD). The decision effectively pushes the ...
Following the successful launch of its financing program generating $1.32 billion in loan demand, Fulcrum Lending Corporation announces A-Note depository program - Fulcrum Treasury NEW YORK, NY / ...
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk ...
? Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik - (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results